These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 8590774)

  • 41. Surgical complications in a hemophilia patient with factor VIII inhibitor and their endovascular management.
    Sadat U; Naik J; Hayes PD
    Vasc Endovascular Surg; 2008; 42(2):168-72. PubMed ID: 18421033
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Frequent but low titre factor VIII inhibitors in haemophilia A patients treated with high purity concentrates.
    Zanon E; Zerbinati P; Girolami B; Bertomoro A; Girolami A
    Blood Coagul Fibrinolysis; 1999 Apr; 10(3):117-20. PubMed ID: 10357004
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Second-generation recombinant factor VIII and inhibitor risk: interpretation of RODIN study findings and implications for patients with haemophilia A.
    van der Bom JG; Gouw SC; Rosendaal FR
    Haemophilia; 2014 Mar; 20(2):e171-4. PubMed ID: 24372628
    [No Abstract]   [Full Text] [Related]  

  • 44. Inhibitor development in previously untreated patients with hemophilia A: a prospective long-term follow-up comparing plasma-derived and recombinant products.
    Kreuz W; Ettingshausen CE; Zyschka A; Oldenburg J; Saguer IM; Ehrenforth S; Klingebiel T
    Semin Thromb Hemost; 2002 Jun; 28(3):285-90. PubMed ID: 12098090
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Intensity of factor VIII treatment and the development of inhibitors in non-severe hemophilia A patients: results of the INSIGHT case-control study.
    van Velzen AS; Eckhardt CL; Peters M; Leebeek FWG; Escuriola-Ettingshausen C; Hermans C; Keenan R; Astermark J; Male C; Peerlinck K; le Cessie S; van der Bom JG; Fijnvandraat K
    J Thromb Haemost; 2017 Jul; 15(7):1422-1429. PubMed ID: 28440011
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Factor VIII inhibitors in patients with hemophilia A: epidemiology of inhibitor development and induction of immune tolerance for factor VIII.
    Kreuz W; Becker S; Lenz E; Martinez-Saguer I; Escuriola-Ettingshausen C; Funk M; Ehrenforth S; Auerswald G; Kornhuber B
    Semin Thromb Hemost; 1995; 21(4):382-9. PubMed ID: 8747701
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cumulative inhibitor incidence in previously untreated patients with severe hemophilia A treated with plasma-derived versus recombinant factor VIII concentrates: a critical systematic review.
    Franchini M; Tagliaferri A; Mengoli C; Cruciani M
    Crit Rev Oncol Hematol; 2012 Jan; 81(1):82-93. PubMed ID: 21277222
    [TBL] [Abstract][Full Text] [Related]  

  • 48. On the treatment of hemorrhage in patients with hemophilia and associated inhibitors.
    Tarantino M; Aledort L
    Transfusion; 2001 Dec; 41(12):1628-9. PubMed ID: 11778084
    [No Abstract]   [Full Text] [Related]  

  • 49. Inhibitor antibody development and T cell response to human factor VIII in murine hemophilia A.
    Qian J; Borovok M; Bi L; Kazazian HH; Hoyer LW
    Thromb Haemost; 1999 Feb; 81(2):240-4. PubMed ID: 10063999
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical efficacy of recombinant activated factor VII (rFVIIa) during acute bleeding episode and surgery in a patient with acquired hemophilia A with high inhibitor titer.
    Franchini M; Capra F; Capelli C; de Maria E; Lippi G; Gandini G
    Haematologica; 2001 Apr; 86(4):E12. PubMed ID: 11325664
    [No Abstract]   [Full Text] [Related]  

  • 51. [Transient inhibitors developed in two cases of hemophilia A].
    Fujiwara F; Kanoh G; Ogawa H; Takaya K; Hibi S; Shima M; Yoshioka A; Imashuku S
    Rinsho Ketsueki; 1997 Dec; 38(12):1263-8. PubMed ID: 9455145
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of factor VIII concentrates on the immune system of patients with hemophilia.
    Mannucci PM
    Thromb Haemost; 1995 Jul; 74(1):437-9. PubMed ID: 8578501
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A.
    Lusher JM; Lee CA; Kessler CM; Bedrosian CL;
    Haemophilia; 2003 Jan; 9(1):38-49. PubMed ID: 12558777
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Inhibitor incidence with recombinant vs. plasma-derived FVIII in previously untreated patients with severe hemophilia A: homogeneous results from four published observational studies.
    Calvez T; Laurian Y; Goudemand J
    J Thromb Haemost; 2008 Feb; 6(2):390-2. PubMed ID: 18036187
    [No Abstract]   [Full Text] [Related]  

  • 55. Measurement of anti-factor VIII IgG, IgG4 and IgM alloantibodies in previously untreated hemophilia A patients treated with recombinant factor VIII. Kogenate Japanese Clinical Study Group.
    Shima M; Sawamoto Y; Nakai H; Kamisue S; Murakami T; Morichika S; Tanaka I; Hayashi K; Yoshioka A
    Int J Hematol; 1995 Jul; 62(1):35-43. PubMed ID: 7670006
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Factors affecting choice of hemostatic agent for the hemophilia patient with an inhibitor antibody.
    Monahan PE; Aledort LM;
    Am J Hematol; 2004 Dec; 77(4):346-50. PubMed ID: 15558804
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Development of inhibitor against hemophilia and prevention and management strategies forpatients with hemophilia].
    Wu RH; Wei QQ
    Zhonghua Er Ke Za Zhi; 2013 Aug; 51(8):631-4. PubMed ID: 24225299
    [No Abstract]   [Full Text] [Related]  

  • 58. Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A.
    Hsu HC; Chen YF; Ho CH
    Zhonghua Yi Xue Za Zhi (Taipei); 1999 Jul; 62(7):450-4. PubMed ID: 10418180
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Inhibitors of factor VIII: detection and treatment.
    Brettler DB
    Southeast Asian J Trop Med Public Health; 1993; 24 Suppl 1():21-5. PubMed ID: 7886576
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparison of anti-human and anti-porcine factor VIII inhibitor levels in 63 patients with severe haemophilia A. A French Multicentric Study.
    Fiks-Sigaud M; Bendelac L; Parquet A; Verroust F; Torchet MF; Berthier AM; Fressinaud E; Guerois C; Aillaud MF; Boneu B
    Vox Sang; 1993; 64(4):210-4. PubMed ID: 8517049
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.